Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

NCT ID: NCT01156415

Last Updated: 2020-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

837 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will assess safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine (AGO178) in patients with Major Depressive Disorder over a 52-week open-label phase.

Cohort I is restricted to include patients who have completed a previous Novartis agomelatine (178C) Double-blind study.

Cohort II will include de-novo patients (those who did not participate in a previous agomelatine 178C study) and will only be open for a limited time span ranging from approximately June to Sept 2010, at which point this cohort II will be closed to enrollment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

agomelatine Major Depressive Disorder MDD depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Agomelatine (AGO178) 0.5 mg

Group Type EXPERIMENTAL

AGO178

Intervention Type DRUG

Agomelatine (AGO178) 1 mg

Group Type EXPERIMENTAL

AGO178

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AGO178

Intervention Type DRUG

AGO178

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documentation of completion of a Novartis AGO178C Double-blind Study in MDD patients.
* Male and female adults, 18 through 71 years of age, inclusive (i.e., same age range as for Double-blind Study, but with upper age limit increased by 1-year to accommodate patients whose age increased during the Double-blind Study).
* Female patients should continue to use effective contraception as defined in double-blind study protocol.



* Male and female adults, 18 through 70 years of age, inclusive.
* Diagnosis of MDD, single or recurrent episode, according to DSM-IV criteria.
* Current episode ≥4 weeks.
* CGI-Severity score ≥4 at Screening and Baseline.

Exclusion Criteria

* Concomitant use of fluvoxamine.
* Any significant medical condition that emerged during Double-blind Phase of a previous study, which may interfere with study participation and/or study assessments as assessed by the investigator.



* History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder (current or during previous one year), obsessive-compulsive disorder.
* Any other current Axis I disorder other than MDD which is the focus of treatment.
* Substance or alcohol abuse in the last 30 days, dependence in the last 6 months.
* Prior exposure to agomelatine.
* Female patients of childbearing potential who are not using effective contraception.
Minimum Eligible Age

18 Years

Maximum Eligible Age

71 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Advanced Research Associates

Glendale, Arizona, United States

Site Status

Southwest Health Ltd dba The Mollen Clinic

Scottsdale, Arizona, United States

Site Status

Clinical Study Centers, LLC

Little Rock, Arkansas, United States

Site Status

Southwestern Research Institute

Beverly Hills, California, United States

Site Status

Comprehensive Neuroscience

Cerritos, California, United States

Site Status

ATP Clinical Research, Inc

Costa Mesa, California, United States

Site Status

Collaborative Neuroscience Network

Garden Grove, California, United States

Site Status

Pharmacology Research Institute

Newport Beach, California, United States

Site Status

Pacific Clinical Research Medical Group

Orange, California, United States

Site Status

CNRI-San Diego, LLC

San Diego, California, United States

Site Status

University of California, San Diego Medical Center

San Diego, California, United States

Site Status

Neuropsychiatric Research Center of Orange County

Santa Ana, California, United States

Site Status

Viking Clinical Research Center

Temecula, California, United States

Site Status

Collaborative Neuroscience

Torrance, California, United States

Site Status

University of Colorado

Aurora, Colorado, United States

Site Status

Western Affiliated Research Institute

Denver, Colorado, United States

Site Status

Middlesex Hospital

Middletown, Connecticut, United States

Site Status

Clinical Studies

Altamonte Springs, Florida, United States

Site Status

Florida Clinical Research Center, LLC

Bradenton, Florida, United States

Site Status

Arocha Research Center

Coral Gables, Florida, United States

Site Status

CNS Clinical Research

Coral Springs, Florida, United States

Site Status

Sjs Clinical Research

Destin, Florida, United States

Site Status

MD Clinical

Hallandale, Florida, United States

Site Status

CNS Healthcare

Jacksonville, Florida, United States

Site Status

Florida Clinical Research Center

Maitland, Florida, United States

Site Status

CNS Healthcare

Orlando, Florida, United States

Site Status

Quantum Lab. at N. Broward Memory Disorder Center

Pompano Beach, Florida, United States

Site Status

Miami Research Associates

South Miami, Florida, United States

Site Status

Comprehensive NeuroScience, Inc.

St. Petersburg, Florida, United States

Site Status

Janus Center for Psychiatric Research

West Palm Beach, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Site Status

Northwest Behavioral Research Center

Marietta, Georgia, United States

Site Status

Hawaii Clinical Research Center

Honolulu, Hawaii, United States

Site Status

Alexian Brothers Center for Psychiatric Research

Hoffman Estates, Illinois, United States

Site Status

Joliet Center for Clinical Research

Joliet, Illinois, United States

Site Status

Capstone Clinical Research

Libertyville, Illinois, United States

Site Status

Rush University Medical Center

Skokie, Illinois, United States

Site Status

Deaconess Clinic Gateway

Newburgh, Indiana, United States

Site Status

Pharmasite Research

Pikesville, Maryland, United States

Site Status

Boston Clinical Trials

Boston, Massachusetts, United States

Site Status

Mount Auburn Medical Associates

Watertown, Massachusetts, United States

Site Status

Coastal Research Associates

Weymouth, Massachusetts, United States

Site Status

Michigan State University

East Lansing, Michigan, United States

Site Status

Pine Rest Christian Mental Health Services

Grand Rapids, Michigan, United States

Site Status

Rochester Center for Behavioral Medicine

Rochester Hills, Michigan, United States

Site Status

Comprehensive Psychiatric Associates

Gladstone, Missouri, United States

Site Status

Robert Wood Johnson Medical School

Piscataway, New Jersey, United States

Site Status

Bio Behavioral Health

Toms River, New Jersey, United States

Site Status

CRI Worldwide

Willingboro, New Jersey, United States

Site Status

Albuquerque Neuroscience

Albuquerque, New Mexico, United States

Site Status

Neurological Associates Of Albany

Albany, New York, United States

Site Status

Social Psychiatry Research, Inc./ SPRI

Brooklyn, New York, United States

Site Status

Neurobehavioral Research, Inc.

Cedarhurst, New York, United States

Site Status

Eastside Comprehensive Medical Service

New York, New York, United States

Site Status

Medical & Behavior Health Research

New York, New York, United States

Site Status

The Medical Research Network, LLC

New York, New York, United States

Site Status

Richmond Behavioral Associates

Staten Island, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Pharmquest

Greensboro, North Carolina, United States

Site Status

Zarzar Psychiatric Associates

Raleigh, North Carolina, United States

Site Status

Piedmont Medical Research Associates, Inc.

Winston-Salem, North Carolina, United States

Site Status

Odyssey Research Services

Fargo, North Dakota, United States

Site Status

Neuro Behavioral Clinical Research

Canton, Ohio, United States

Site Status

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Site Status

North Star Medical Research

Cleveland, Ohio, United States

Site Status

The Ohio State Universtiy - Harding Hospital

Columbus, Ohio, United States

Site Status

Neurology & Neuroscience Center of Ohio

Toledo, Ohio, United States

Site Status

IPS Research

Oklahoma City, Oklahoma, United States

Site Status

SP Research

Oklahoma City, Oklahoma, United States

Site Status

Cutting Edge Research

Oklahoma City, Oklahoma, United States

Site Status

Sunstone Medical Research, LLC

Medford, Oregon, United States

Site Status

Oregon Center for Clinical Investigations

Portland, Oregon, United States

Site Status

Summit Research

Portland, Oregon, United States

Site Status

Lehigh Center for Clinical Research

Allentown, Pennsylvania, United States

Site Status

Suburban Research Associates

Media, Pennsylvania, United States

Site Status

CRI Worldwide, LLC

Philadelphia, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Clinical Neuroscience Solutions, Inc.

Memphis, Tennessee, United States

Site Status

Research Strategies of Memphis

Memphis, Tennessee, United States

Site Status

Clinical Research Associates

Nashville, Tennessee, United States

Site Status

Millwood Hospital

Arlington, Texas, United States

Site Status

FutureSearch Trials of Dallas

Dallas, Texas, United States

Site Status

InSite Clinical Research

DeSoto, Texas, United States

Site Status

Bayou City Research Limited

Houston, Texas, United States

Site Status

Claghorn Lesem Research Clinic, Inc.

Houston, Texas, United States

Site Status

Texas Center for Drug Development

Houston, Texas, United States

Site Status

Grayline Clinical Drug Trials

Wichita Falls, Texas, United States

Site Status

Radiant Research

Salt Lake City, Utah, United States

Site Status

University of Utah Mood Disorders Clinic

Salt Lake City, Utah, United States

Site Status

Alliance Research Group, LLC

Richmond, Virginia, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

Frontier Institute

Spokane, Washington, United States

Site Status

Independent Psychiatric Consultants

Waukesha, Wisconsin, United States

Site Status

Centro de Investigacion Clinica Psiquiatrica

Ponce, , Puerto Rico

Site Status

Dharma Institute and Research Center

San Juan, , Puerto Rico

Site Status

INSPIRA Clinical Research

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Related Links

Access external resources that provide additional context or updates about the study.

https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7243

Results for CAGO178C2399 from the Novartis Clinical Trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAGO178C2399

Identifier Type: -

Identifier Source: org_study_id